These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 2239587

  • 1. [Clinical effect of oxybutynin hydrochloride (1 mg/tablet)].
    Yokoyama E, Fujino A, Kubo S, Mashimo S, Koshiba K.
    Hinyokika Kiyo; 1990 Jul; 36(7):869-76. PubMed ID: 2239587
    [Abstract] [Full Text] [Related]

  • 2. [Effects of long-term administration of oxybutynin hydrochloride (KL007) for the treatment of neurogenic bladder and unstable bladder].
    Sonoda T, Sakurai T, Yamada K, Mizutani S, Tsujimoto Y, Ogawa T.
    Hinyokika Kiyo; 1989 Jan; 35(1):167-78. PubMed ID: 2658513
    [Abstract] [Full Text] [Related]

  • 3. [Clinical effects of oxybutynin hydrochloride on neurogenic bladder].
    Toma H, Nakamura R.
    Hinyokika Kiyo; 1986 Jun; 32(6):907-11. PubMed ID: 3532726
    [Abstract] [Full Text] [Related]

  • 4. [Clinical effects of oxybutynin hydrochloride (Pollakis)--especially in the treatment of pollakisuria, urgency and urinary incontinence].
    Yamauchi K, Ohashi K, Osanai H, Inagaki N, Yamaguchi S, Hashimoto H, Yachiku S.
    Hinyokika Kiyo; 1990 Dec; 36(12):1485-90. PubMed ID: 2075888
    [Abstract] [Full Text] [Related]

  • 5. [Clinical effects of oxybutynin hydrochloride in the treatment of unstable bladder and overactive neurogenic bladder: a long-term clinical trial].
    Goto M, Kato K, Kondo A, Otani T, Takita T, Kobayashi M.
    Hinyokika Kiyo; 1988 Mar; 34(3):541-50. PubMed ID: 3389295
    [Abstract] [Full Text] [Related]

  • 6. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
    Yokoyama O, Ishiura Y, Nakamura Y, Ohkawa M.
    Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182
    [Abstract] [Full Text] [Related]

  • 7. [Clinical effectiveness of KL 007 (oxybutynin hydrochloride) in urinary disorders].
    Takimoto Y, Kiyotaki S, Kawazoe K, Fuse T, Kitamura K, Yamamoto T, Satoh Y, Okada K, Kishimoto T.
    Hinyokika Kiyo; 1985 Dec; 31(12):2284-301. PubMed ID: 3832931
    [Abstract] [Full Text] [Related]

  • 8. Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder.
    Mizunaga M, Miyata M, Kaneko S, Yachiku S, Chiba K.
    Paraplegia; 1994 Jan; 32(1):25-9. PubMed ID: 8015832
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ, Lemack GE, Foote JE, Trop CS.
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [Abstract] [Full Text] [Related]

  • 10. [Clinical studies of terodiline hydrochloride and clenbuterol hydrochloride for urinary frequency and incontinence].
    Katsumi T, Murayama K, Tajika E, Nakamura T, Kawaguchi K.
    Hinyokika Kiyo; 1991 Nov; 37(11):1575-80. PubMed ID: 1767784
    [Abstract] [Full Text] [Related]

  • 11. [Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women].
    Serrano Brambila EA, Quiroga Avila RG, Lorenzo Monterrubio JL, Moreno Aranda J.
    Ginecol Obstet Mex; 2000 Apr; 68():174-81. PubMed ID: 10824450
    [Abstract] [Full Text] [Related]

  • 12. [Assessment of the use of oxybutynin hydrochloride (Pollakisu tablets) in the elderly].
    Uchibayashi T, Nakajima K, Nihino A, Hisazumi H.
    Hinyokika Kiyo; 1991 Sep; 37(9):1077-85. PubMed ID: 1785418
    [Abstract] [Full Text] [Related]

  • 13. [Topical treatment with oxybutynin chloride in neurogenic incontinence].
    López Pereira P, Martínez MJ, Muguerza R, Jaureguizar E.
    Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234
    [Abstract] [Full Text] [Related]

  • 14. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM.
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction.
    Franco I, Horowitz M, Grady R, Adams RC, de Jong TP, Lindert K, Albrecht D.
    J Urol; 2005 Jan; 173(1):221-5. PubMed ID: 15592080
    [Abstract] [Full Text] [Related]

  • 16. [Clinical effect of terodiline hydrochloride on pollakisuria and urinary incontinence].
    Sugiyama T, Kiwamoto H, Uchida A, Nagai N, Park YC, Kurita T, Ikegami M, Nakanishi A, Kawamura M, Umekawa T.
    Hinyokika Kiyo; 1990 Nov; 36(11):1371-7. PubMed ID: 2288317
    [Abstract] [Full Text] [Related]

  • 17. [Clinical evaluation of bunazosin hydrochloride for the treatment of voiding disturbances due to neurogenic bladder--a double-blind study].
    Koyanagi T, Togashi M, Maru A, Orikasa S, Soma F, Shimazaki J, Yasuda K, Aso Y, Honma Y, Miyake K.
    Hinyokika Kiyo; 1990 Oct; 36(10):1233-52. PubMed ID: 1979900
    [Abstract] [Full Text] [Related]

  • 18. [Therapeutic effects of intrarectal administration of oxybutynin].
    Radziszewski P, Borkowski A.
    Wiad Lek; 2002 Oct; 55(11-12):691-8. PubMed ID: 12715351
    [Abstract] [Full Text] [Related]

  • 19. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
    Fader M, Glickman S, Haggar V, Barton R, Brooks R, Malone-Lee J.
    J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
    [Abstract] [Full Text] [Related]

  • 20. [Experience in the use of propiverine hydrochloride (P-4) for patients suffering from urinary frequency and/or incontinence].
    Yokoyama O, Miyazaki K, Ishida T, Fujita Y, Hisazumi H.
    Hinyokika Kiyo; 1990 Apr; 36(4):517-23. PubMed ID: 2378310
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.